Introduction

Theregen's product development program for Anginera is based on Dermagraft™, a qualified cell bank, cell-based wound management product.
View Dermagraft background

The Anginera technology platform applies a solid foundation of proven research into the cardiovascular arena. Backed by compelling animal data in several heart models, Theregen scientists have advanced into clinical studies in the human heart.

Anginera Technology
Anginera's technology uses a qualified cell bank of human fibroblast cells. The fibroblast cells are cultured on a three-dimensional bioabsorbable scaffold material to create a viable tissue.
View growth factor review

When applied as an epicardial patch to an ischemic area of the heart, the living tissue provides cytokines and growth factors needed to induce angiogenesis and tissue repair. Preclinical studies provide evidence that Anginera supports improved cardiac function in a chronic ischemic heart model. A major benefit of Anginera treatment may be the improvement of blood flow to areas of the heart that are not treatable by conventional revascularization therapies (e.g., CABG and stents).

Anginera is identical to the wound-healing product, Dermagraft™, that was developed at the former Advanced Tissue Sciences. Dermagraft has been clinically proven to be safe and effective, and has been used to treat over 30,000 patients for diabetic foot ulcers.